Technology
Health
Pharmaceutical

Intec Pharma

$5.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (3.70%) Today
+$0.03 (0.52%) After Hours

Why Robinhood?

You can buy or sell Intec Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Intec Pharma Ltd. Ordinary Shares, also called Intec Pharma, is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Read More Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.

Employees
83
Headquarters
Jerusalem, Jerusalem
Founded
2000
Market Cap
177.48M
Price-Earnings Ratio
Dividend Yield
Average Volume
202.52K
High Today
$5.44
Low Today
$5.15
Open Price
$5.15
Volume
172.18K
52 Week High
$9.25
52 Week Low
$3.55

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Asia (Non-China)
Asia

News

Seeking AlphaMay 16

Intec Pharma +14% on Merck collaboration

Intec Pharma (NASDAQ:NTEC) has entered into an agreement with Merck (NYSE:MRK), to explore using the Accordion Pill (AP) platform for an undisclosed development program.

490
Yahoo FinanceMay 10

Fibromyalgia Treatment Market to Surpass US$ 3,607.3 Million by 2026 – Coherent Market Insights

SEATTLE, May 10, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the fibromyalgia treatment market was valued at US$ 2,778.6 million in 2018 and is projected to exhibit a CAGR of 3.3% over the forecast period (2018–2026). Key Trends and Analysis of the Fibromyalgia Treatment Market: Key players in the market are involved in robust research and development activities for the development of novel therapies indicated for treatment of fibromyalgia. Launch of novel treatments is expected to sig...

285
Yahoo FinanceMay 7

Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update

38

Earnings

-$0.40
-$0.37
-$0.34
-$0.31
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.